Evidence map›Paper›PMID 42599895›Full record

ArticleClinical journal of oncology nursing2025

Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles.

Carrie Bellerive, Ann McNeill, Beth Faiman, Tiffany A Richards

Abstract read
In one paragraph

Article in Clinical journal of oncology nursing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carrie BelleriveCarrie Bellerive.
Ann McNeillAnn McNeill.
Beth FaimanBeth Faiman.
Tiffany A RichardsTiffany A. Richards.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe evolving landscape of oncology treatment, particularly in the realm of multiple myeloma immunotherapy, presents new challenges and opportunities for healthcare providers and, of note, nurses. Innovative treatments like chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have revolutionized care for patients with relapsed and refractory multiple myeloma.

objectivesThis article underscores the role of nurses in managing care transitions, emphasizing their responsibilities in patient education, coordination of care, and the seamless handoff between treatment phases.

methodsThrough a review of existing literature and knowledge gained from expert opinions and experiences, this article presents recommendations for nurses managing care transitions.

findingsEffective transitions of care optimize patient outcomes, minimize barriers to access, and ensure continuity of care for patients undergoing complex treatments like CAR T-cell therapy and bispecific antibodies. These therapies require meticulous coordination during transitions of care.

Indexed as

bispecific antibodiescare transitionsCAR T-cell therapymultiple myeloma

Identifiers

PMID42599895
PMCPMC12056808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.